Shots:

• The EC has granted marketing authorization for Alvotech’s adalimumab biosimilar AVT02 to reference Humira. In Sept., the product received a recommendation for approval from the EMA’s CHMP includes all EU Member States along with countries in the EEA, Iceland, Liechtenstein, and Norway
• AVT02 is a high concentration biosimilar to Humira (adalimumab) which is used for autoimmune and inflammatory conditions
• On Dec. 7, 2021, Alvotech entered into a definitive business combination agreement with Oaktree & combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO”, following the completion of the transaction

Ref: Businesswire | Image: Alvotech